Article date: August 2013
We have launched a public consultation on the continued availability of oral diclofenac as a pharmacy (P) medicine and in particular on risk-minimisation measures advised by the Commission on Human Medicines.
Any comments can be emailed to email@example.com; alternatively they may be addressed to: Colette McCreedy, Self Medication Specialist and Unit Manager, MHRA, 3rd Floor, 151 Buckingham Palace Road, London SW1W 9SZ.
Comments must arrive no later than 28 October 2013 to be taken into account.
Article citation: Drug Safety Update vol 7 issue 1, August 2013: O2.